DS2243-054

Open-label, Multicenter, First-in-Human Phase 1 Study of DS-2243a in Participants With Advanced Solid Tumors

  • NKI code: M24FDS
  • Company code: DS2243-054
  • Code clinicaltrials.gov: NCT06644755

Principal investigator

Prof. Dr. N. Steeghs

Medication

DS-2243a HLA-A2/NY-ESO x CD3 bispecific T-cell engager

Summary

The purpose of the study is to investigate the safety of the new drug DS-2243a and how well it works. DS-2243a is being tested in different strengths in patients with cancer to determine the best dose.

Read more on clinicaltrials.gov.

Notes

  • Synovial sarcoma – open
  • Myxoid/round cell liposarcoma – open
  • NSCLC – closed
  • Urothelial carcinoma – closed
onload